Video

Predicting rituximab responses in lupus remains challenging

Publish date: July 6, 2018

 

REPORTING FROM THE EULAR 2018 CONGRESS

SOURCE: Sánchez Pérez H and Isenberg D. Ann Rheum Dis. 2018;77(Suppl 2):177. EULAR 2018 Congress, Abstract OP0255.

Pages

Recommended Reading

Median time to progression from discoid to systemic lupus may be less than a year
MDedge Dermatology
Timely dermatomyositis diagnosis, treatment remain elusive
MDedge Dermatology
Hydroxychloroquine throws off Quantiferon-TB Gold results, study finds
MDedge Dermatology
Cutaneous lupus: Switching antimalarials can delay immunosuppressive therapy
MDedge Dermatology
Long-term follow-up most important for hydroxychloroquine retinal screening
MDedge Dermatology
Pemphigus remission rate tops 80% with rituximab
MDedge Dermatology
Baricitinib shows potential as lupus treatment
MDedge Dermatology
LLDAS shows potential as routine lupus treatment target
MDedge Dermatology
SLE classification criteria perform well in validation study
MDedge Dermatology
New SLE classification criteria reset disease definition
MDedge Dermatology